JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV
Open Access
- 29 April 2024
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (5) , e29631
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1Cell Host & Microbe, 2024
- Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitutionThe Lancet Microbe, 2024
- Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variantsCell, 2024
- Virological characteristics of the SARS-CoV-2 JN.1 variantThe Lancet Infectious Diseases, 2024
- Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional studyVaccine, 2023
- Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressureThe Lancet Infectious Diseases, 2023
- Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIVVaccines, 2023
- Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccinationThe Lancet Infectious Diseases, 2023
- SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 RatioVaccines, 2023
- Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIVViruses, 2023